Benjamin Machinas Beneski - 02 Feb 2026 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role: SVP, Chief Technical Officer
Signature: /s/Earl Douglas, Attorney-in-Fact
Issuer symbol: ALLO
Transactions as of: 02 Feb 2026
Net transactions value: -$13,060
Form type: 4
Filing time: 04 Feb 2026, 17:20:22 UTC
Previous filing: 19 Nov 2025
Next filing: 04 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Beneski Benjamin Machinas	SVP, Chief Technical Officer	210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO	/s/Earl Douglas, Attorney-in-Fact	04 Feb 2026	0002057918

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALLO	Common Stock	Sale	$13,060	-7,549	-3.5%	$1.73	210,172	02 Feb 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALLO	Stock Option (Right to buy)	Award	$0	+373,757		$0.000000	373,757	02 Feb 2026	Common Stock	373,757	$1.87	Direct	F3
transaction	ALLO	Restricted Stock Unit	Award	$0	+105,720		$0.000000	105,720	02 Feb 2026	Common Stock	105,720		Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3	25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F4	Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.